Skip to main content
OpenTrials
Completed

NCT Number: NCT00419757

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration(FDA)) in the Hispanic population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Research Site, Aguas Buenas, Puerto Rico

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or Female, Hispanic (self-reported), > 12 years of age
  • Moderate to severe asthma requiring treatment with an inhaled corticosteroid
  • Diagnosis of asthma for at least 6 months

Exclusion criteria

  • Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)
  • Any significant disease or disorder that may jeopardize a subject's safety

Treatment and study plan

Budesonide/formoterol (SYMBICORT) pMDI

Drug

SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily

Budesonide HFA pMDI

Drug

Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily

Primary outcomes

  1. Morning Peak Expiratory Flow (AM PEF)

    Time frame: Baseline (run-in) and throughout 12 weeks

    Change from baseline (average of daily records over the 14 days of run-in) to the average of daily records over the treatment period of 12 weeks, with baseline value as covariate.

Secondary outcomes

  1. Percentage of Participants With Pre-defined Asthma Events

    Time frame: 12 weeks

    Asthma Events, defined as any of: decrease in lung function (FEV1 or AM PEF), use of rescue medication over maximum allowed per day, night awakening requiring use of rescue medication, exacerbation of asthma requiring medical assistance, use of not allowed asthma medication

  2. Percentage of Participants With "Withdrawals Due to Pre-defined Asthma Events"

    Time frame: 12 weeks

    Percentage of participants with "Withdrawals Due to Pre-defined Asthma Events" as recorded in CRF. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.

  3. Changes Pre-dose Forced Expiratory Volume in 1 Second (FEV1)

    Time frame: Baseline, 2, 6 and 12 weeks

    Changes in pre-dose FEV1 from baseline to the average value over the treatment period, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.

  4. Change From Baseline in a Evening Peak Expiratory Flow (PM PEF)

    Time frame: Baseline (run-in) and throughout 12 weeks

    Change from baseline (average of daily records over the 14 days of run-in) to the average of daily records over the treatment period of 12 weeks with baseline as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.

  5. Change in Nighttime Asthma Symptom Score From Baseline Through 12 Weeks

    Time frame: Baseline (run-in) and throughout 12 weeks

    Change from baseline in average of daily scores for nighttime asthma over 12 weeks of treatment, with baseline value as covariate.

    Daily scale:

    • 0 = No symptoms
    • 1 = Mild symptoms
    • 2 = Moderate symptoms
    • 3 = Severe symptoms
  6. Change in Daytime Asthma Symptom Score From Baseline Through 12 Weeks

    Time frame: Baseline (run-in) and throughout 12 weeks

    Change from baseline in average of daily scores for daytime asthma over 12 weeks of treatment, with baseline value as covariate.

    Daily scale:

    • 0 = No symptoms
    • 1 = Mild symptoms
    • 2 = Moderate symptoms
    • 3 = Severe symptoms
  7. Change in Asthma Related Awakenings Free Nights, From Baseline Through 12 Weeks

    Time frame: Baseline (run-in) and throughout 12 weeks

    Change from baseline in percentage of nights with awakenings due to asthma over 12 weeks of treatment, with baseline value as covariate.

  8. Change From Baseline in Rescue Medication Use Over 12 Weeks of Treatment

    Time frame: Baseline (run-in) and throughout 12 weeks

    Change from baseline in rescue medication use over 12 weeks of treatment with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.

  9. Change From Baseline in Rescue-free Days Over 12 Weeks of Treatment

    Time frame: Baseline (run-in) and throughout 12 weeks

    Change from baseline in percentage of rescue-free days over 12 weeks of treatment, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.

  10. Change From Baseline in Symptom-free Days Over 12 Weeks of Treatment

    Time frame: Baseline (run-in) and throughout 12 weeks

    Change from baseline in percentage of symptom-free days over 12 weeks of treatment, with baseline value as covariate. Includes all subjects who were randomised, took at least one dose of study medication and contributed sufficient data for the endpoint to be calculated.

  11. Subject Global Assessment

    Time frame: Baseline and week 12

    The assessment was made using a 5-point Likert scale with 1=much better, 2=somewhat better, 3=comparable, 4=somewhat worse, and 5=much worse transformed to a binary variable with points 1 and 2 combined as "Yes" and points 3, 4, 5 as "No". Percent of Participants that gave positive responses.

  12. Physician Global Assessment

    Time frame: Baseline and week 12

    The assessment was made using a 5-point scale with 1=much better, 2=somewhat better, 3=comparable, 4=somewhat worse, and 5=much worse transformed to a binary variable with points 1and 2 combined as "Yes" and points 3, 4, 5 as "No". Percent of Participants that gave positive responses.

  13. Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Control Relief Index

    Time frame: Week 12

    Mean scores (6-points scale, where 1-means the most positive opinion and 6-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0±100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.

  14. Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Overall Perception of Medication

    Time frame: Week 12

    Mean scores (6 or 5-points scale, where 1-means the most positive opinion and 5/6-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0±100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.

  15. Patient Satisfaction With Asthma Medication (PSAM) in Term of Domain: Comparison With Other Medications

    Time frame: Week 12

    Mean scores (5-points scale, where 1-means the most positive opinion and 5-the most negative opinion) were calculated for items in domain. 6-point response options were scored on a 0±100 scale, where 100 represented the highest level of satisfaction and 0 the lowest level of satisfaction.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A 12-week, Randomised, Double Blind, Active-controlled, Multi-centre, Phase IIIB Study Comparing the Efficacy and Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily Versus Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily, in Adult/Adolescent (> 12 Yrs) Hispanic Subjects With Asthma

Important dates

Study start
2007
Primary completion
2008
Study completion
2008
First posted
Jan 9, 2007
Registry last updated
Aug 27, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.